Search

Your search keyword '"Steichen O"' showing total 512 results
Start Over Author "Steichen O"
512 results on '"Steichen O"'

9. Caractéristiques des patients admis en médecine interne dans 18 hôpitaux français en aval des urgences et organisation de ces services : enquête transversale de la SNFMI (groupe d’étude SiFMI) en 2015

Author

Delforge, J., Sovaila, S., Alix, L., Didon, A., Steichen, O., Ranque, B., Froissart, A., Amadou, K., Hanslik, T., Cador, B., Bergmann, J.F., Mekininan, A., Goujard, C., Gayet, S., Cathebras, P., Fantin, B., Raigniac, D., Weber, J.C., Rosenthal, E., Hery, L., Andres, E., Benhamou, Y., and Bourgarit, A.

Published
2021
Full Text
View/download PDF

10. Shift in emergency department utilization by frequent attendees with sickle cell disease during the COVID‐19 pandemic: A multicentre cohort study.

Author

Rech, J. S., Cohen, A., Bartolucci, P., Santin, A., Chantalat Auger, C., Affo, L., Le Jeune, S., Arlet, J. B., Boëlle, P. Y., and Steichen, O.

Subjects
EMERGENCY room visits, STAY-at-home orders, EMERGENCY medical services, SICKLE cell anemia, PUBLIC health
Abstract

Summary: While the coronavirus disease‐2019 (COVID‐19) might have increased acute episodes in people living with sickle cell disease (SCD), it may also have changed their reliance on emergency department (ED) services. We assessed the impact of the COVID‐19 pandemic and lockdowns on ED visits in adult SCD people followed in five French reference centres, with a special focus on 'high users' (≥10 visits in 2019). We analysed the rate of ED visits from 1 January 2015 to 31 December 2021, using a self‐controlled case series. Among 1530 people (17 829 ED visits), we observed a significant reduction in ED visits during and after lockdowns, but the effect vanished over time. Compared to pre‐pandemic, incidence rate ratios for ED visits were 0.59 [95% CI 0.52–0.67] for the first lockdown, 0.66 [95% CI 0.58–0.75] for the second and 0.85 [95% CI 0.73–0.99] for the third. High users (4% of people but 33.7% of visits) mainly drove the reductions after the first lockdown. COVID‐19 lockdowns were associated with reduced ED visits. While most people returned to their baseline utilization by April 2021, high users had a lasting decrease in ED visits. Understanding the factors driving the drop in ED utilization among high users might inform clinical practice and health policy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Évaluation multidisciplinaire de patients souffrant de symptômes persistants après la COVID-19 : caractéristiques cliniques, diagnostics retenus et satisfaction à l’égard du programme

Author

Ranque, B., primary, Gouraud, C., additional, Xiang, K., additional, Arlet, J.B., additional, Cheminet, G., additional, Flamarion, E., additional, Getten, P., additional, Lafont, E., additional, Michon, A., additional, Senot, N., additional, Steichen, O., additional, Tennenbaum, J., additional, Vanjak, A., additional, and Lemogne, C., additional

Published
2023
Full Text
View/download PDF

29. Risque d’insuffisance rénale aiguë après injection de produit de contraste iodé chez les adultes atteints de drépanocytose : une série de cas autocontrôlés issue d’un entrepôt de données de santé multicentrique

Author

Azoyan, L., primary, Lombardi, Y., additional, Rech, J.S., additional, Haymann, J.P., additional, Wu, C., additional, Le Jeune, S., additional, Affo, L., additional, Chantalat Auger, C., additional, Bartolucci, P., additional, Leblanc, J., additional, and Steichen, O., additional

Published
2022
Full Text
View/download PDF

42. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

Author

Amar, L., Pacak, K., Steichen, O., Akker, S.A., Aylwin, SJB, Baudin, E., Buffet, A., Burnichon, N., Clifton-Bligh, R.J., Dahia, PLM, Fassnacht, M., Grossman, A.B., Herman, P., Hicks, R.J., Januszewicz, A., Jimenez, C., Kunst, HPM, Lewis, D., Mannelli, M., Naruse, M., Robledo, M., Taïeb, D., Taylor, D.R., Timmers, HJLM, Treglia, G., Tufton, N., Young, W.F., Lenders, JWM, Gimenez-Roqueplo, A.P., and Lussey-Lepoutre, C.

Subjects
Adult, Aged, Algorithms, Asymptomatic Diseases, Child, Consensus, Genetic Carrier Screening/methods, Genetic Carrier Screening/standards, Genetic Testing/standards, Germ-Line Mutation, Heterozygote, Humans, Internationality, Mass Screening/methods, Mass Screening/standards, Monitoring, Physiologic/methods, Monitoring, Physiologic/standards, Succinate Dehydrogenase/genetics
Abstract

Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA, SDHB, SDHC and SDHD), which encode the four subunits of the SDH enzyme. When a pathogenic SDHx mutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carry SDHx mutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rare SDHx-related tumours and management of elderly people who have an SDHx mutation. This Consensus Statement focuses on the management of asymptomatic SDHx mutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.

Published
2021

45. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

Author

Amar, L, Pacak, K, Steichen, O, Akker, SA, Aylwin, SJB, Baudin, E, Buffet, A, Burnichon, N, Clifton-Bligh, RJ, Dahia, PLM, Fassnacht, M, Grossman, AB, Herman, P, Hicks, RJ, Januszewicz, A, Jimenez, C, Kunst, HPM, Lewis, D, Mannelli, M, Naruse, M, Robledo, M, Taieb, D, Taylor, DR, Timmers, HJLM, Treglia, G, Tufton, N, Young, WF, Lenders, JWM, Gimenez-Roqueplo, A-P, Lussey-Lepoutre, C, Amar, L, Pacak, K, Steichen, O, Akker, SA, Aylwin, SJB, Baudin, E, Buffet, A, Burnichon, N, Clifton-Bligh, RJ, Dahia, PLM, Fassnacht, M, Grossman, AB, Herman, P, Hicks, RJ, Januszewicz, A, Jimenez, C, Kunst, HPM, Lewis, D, Mannelli, M, Naruse, M, Robledo, M, Taieb, D, Taylor, DR, Timmers, HJLM, Treglia, G, Tufton, N, Young, WF, Lenders, JWM, Gimenez-Roqueplo, A-P, and Lussey-Lepoutre, C

Abstract

Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA, SDHB, SDHC and SDHD), which encode the four subunits of the SDH enzyme. When a pathogenic SDHx mutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carry SDHx mutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rare SDHx-related tumours and management of elderly people who have an SDHx mutation. This Consensus Statement focuses on the management of asymptomatic SDHx mutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results